Therapeutic Solutions International Receives Notice of Allowance for Landmark Patent Covering Cellular Therapy of Lung Diseases

Rhea-AI Summary

Therapeutic Solutions International (TSOI) has received a Notice of Allowance from the US Patent and Trademark Office for a patent on using T regulatory cells to enhance the efficacy of mesenchymal stem cells in treating lung inflammation. This patent covers a method to reduce lung inflammation through the administration of T regulatory cells combined with mesenchymal stem cells. The company is developing treatments for COVID-19, ARDS, COPD, and pulmonary fibrosis, all involving lung inflammation. The patent is expected to increase TSOI's value, with comparisons to successful deals in the sector, such as Regeneron-Sonoma and Quell-AstraZeneca.

Positive

• TSOI received a Notice of Allowance for a patent enhancing stem cell therapy efficacy.
• Patent covers methods reducing lung inflammation using T regulatory cells and mesenchymal stem cells.
• Potential for increased company value due to the new patent.
• Company holds a Phase III Investigational New Drug application for treating COVID-19.
• New application targeted at treating all-cause ARDS.
• Filed a Phase I/II clinical trial for COPD and has preclinical data for pulmonary fibrosis.
• Positive market potential comparisons with Regeneron-Sonoma and Quell-AstraZeneca deals.

Negative

• Uncertainty regarding the success and commercialization of new applications for treating ARDS.
• Filed clinical trials and preclinical data imply ongoing research and potential delays in treatment availability.
• No concrete financial data disclosed regarding recent developments.

Clinical Stage Stem Cell Company Granted Exclusivity on the Use of Specific Immune System Cells to Increase Efficacy of Stem Cells in Lung Inflammation

ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International, Inc. (TSOI) announced today receipt of a Notice of Allowance from the United States Patent and Trademark Office regarding its patent application entitled “Stimulation of Mesenchymal Stem Cell Therapeutics Activities by Regulatory T Cells.”

The issued patent claims include:

“A method of inhibiting lung inflammation comprising: a) identifying a subject suffering from lung inflammation; b) administering a population of T regulatory cells in combination with a population of plastic adherent umbilical cord derived mesenchymal stem cells in an amount sufficient to reduce inflammation in said subject’s lungs.”

Therapeutic Solutions International owns a Phase III Investigational New Drug application for treatment of COVID-19. However, the Company is working on a new application for treating “all-cause” acute respiratory distress syndrome (ARDS) using the company’s patented JadiCell¹, a true mesenchymal stem cell. Additionally, the Company has filed a Phase I/II clinical trial for COPD and possesses preclinical data for pulmonary fibrosis. All of these conditions are examples of lung inflammation.

“The claims issued today, in our opinion, capture the whole area of using a specific type of immune system cell, termed ‘T Regulatory Cells’ for enhancing activity of mesenchymal stem cells in all the major lung pathologies,” said Dr. Thomas Ichim, Board Member of TSOI and co-inventor of the patent. “We anticipate significant value in the current patent based on other companies working in the area of T regulatory cells. This is validated by the Regeneron-Sonoma Therapeutics² and the Quell-AstraZeneca³ deals. It is nice to know that we own a potent piece of intellectual property that anyone hoping to enter this space will need to license.”

Dr. Ichim has a strong history of success in the area of biotechnology having taken his company Medistem from a 7 cent share price when he was made CEO to a sale at $1.35 to Intrexon, a NYSE traded company. Dr. Ichim’s lifetime of science, FDA clearances, and over 400 issued and published patents, have taken multiple companies to NASDAQ public listings.

“At Therapeutic Solutions International we are building a critical mass of clinical data, scientific discoveries, and patents⁴,” said Timothy Dixon, President, and CEO of the Company and co-inventor. “We believe we are developing significant traction which will result in partnerships and co-development deals.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

1 https://patents.google.com/patent/US9803176B2/en?oq=9803176
2 https://www.fiercebiotech.com/biotech/sonoma-biotherapeutics-takes-big-bite-120m-regeneron-collab-tacking-five-new-targets
3 https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-signs-2-bln-agreement-with-quell-develop-cell-therapies-2023-06-09/
4 https://patents.justia.com/assignee/therapeutic-solutions-international-inc

View source version on businesswire.com: https://www.businesswire.com/news/home/20240516930973/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International, Inc.

FAQ

What recent patent did Therapeutic Solutions International receive?

TSOI received a Notice of Allowance for a patent covering the use of T regulatory cells to enhance the efficacy of mesenchymal stem cells in treating lung inflammation.

How does the new TSOI patent aim to treat lung inflammation?

The patent involves administering T regulatory cells combined with mesenchymal stem cells to reduce lung inflammation.

What conditions is TSOI targeting with their new patent?

TSOI is targeting COVID-19, acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis.

What is the potential impact of TSOI's new patent on its market value?

The new patent is expected to increase TSOI's market value, drawing parallels to successful deals in the field, such as Regeneron-Sonoma and Quell-AstraZeneca.

What are TSOI’s current clinical developments related to lung diseases?

TSOI holds a Phase III Investigational New Drug application for COVID-19, a Phase I/II clinical trial for COPD, and preclinical data for pulmonary fibrosis.